Drug Pricing Activity At US FDA May Be Unique To Gottlieb Tenure

Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.

US dollars and pills
The US FDA likely is not the primary agency for drug pricing work, a long-time stakeholder argued. • Source: Shutterstock

Scott Gottlieb’s skill set may have facilitated a new, but likely temporary, foray by the US Food and Drug Administration into the drug pricing arena as his follower does not possess the same qualifications to lead on the issue.

Agency stakeholders were surprised when Gottlieb became commissioner in 2017 calling for a more active FDA role lowering drug prices....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

Quotable: Top Experts On Policy Hot Topics

 

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By 

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.